Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer’s disease (2015)

Peer-Reviewed Study · Wischik CM, Staff RT, Wischik DJ, Bentham P, Murray AD, Storey JM, Kook KA, Harrington CR · 2015

Wischik CM et al., 2015: Peer-reviewed report of the Rember phase 2 trial (NCT00515333): 321 patients, three active dose levels of methylthioninium at 69, 138 and 228 mg/day, 24 weeks plus blinded extensions. The 138 mg/day group showed a treatment effect on ADAS-cog in moderate patients and on cerebral blood flow in mild patients.

An exploratory double-blind, randomized, placebo-controlled, dose-finding trial of MT (69, 138, and 228 mg/day) was conducted in 321 mild/moderate AD subjects.

Wischik CM et al., 2015: Peer-reviewed report of the Rember phase 2 trial (NCT00515333): 321 patients, three active dose levels of methylthioninium at 69, 138 and 228 mg/day, 24 weeks plus blinded extensions. The 138 mg/day group showed a treatment effect on ADAS-cog in moderate patients and on cerebral blood flow in mild patients. Study type: randomised, double-blind, placebo-controlled phase 2 (exploratory dose-finding). N=321 randomised (registry says 323 actual enrolment). Country: UK/Singapore sites (Aberdeen analysis centre). Drug: methylthioninium chloride (methylene blue) oral capsules, nominal 30/60/100 mg three times daily, reported as delivered 69/138/228 mg/day, 24 weeks then 6- and 12-month blinded extensions. Funder: TauRx Therapeutics (authors affiliated with TauRx; Wischik is TauRx founder/chairman). Comparator: placebo. Authors' own caveats quoted: 'The delivery of the highest dose was impaired due to dose-dependent dissolution and absorption limitations.' Note the title calls the study 'exploratory'; the pre-specified positive result is confined to the 138 mg/day dose and to subgroups (moderate patients on ADAS-cog; mild patients on SPECT blood flow), not the whole cohort. Also filed as MTC-006, MTK-16, MTC-072 (claims C1, C11, C3, C5). Study type: randomized trial.